title: [Grading of lung cancer].
abstract: In comparison with other tumor entities there is no common generally accepted grading system for lung cancer with clearly defined criteria and clinical relevance. In the recent fourth edition of the World Health Organization (WHO) classification from 2015 of tumors of the lungs, pleura, thymus and heart, there is no generally applicable grading for pulmonary adenocarcinomas, squamous cell carcinomas or rarer forms of carcinoma. Since the new IASLC/ATS/ERS classification of adenocarcinomas published in 2011, 5 different subtypes with significantly different prognosis are proposed. This results in an architectural (histologic) grading, which is usually applied to resection specimens. For squamous cell carcinoma the number of different histological subtypes in the new WHO classification was reduced compared to earlier versions but without a common grading system. In recent publications nesting and budding were proposed as the main (histologic) criteria for a grading of squamous cell carcinomas. The grading of neuroendocrine tumors (NET) of the lungs in comparison with NET in other organs is presented in a separate article in this issue. Certain rare tumor types are high grade per definition: small cell, large cell and pleomorphic carcinomas, carcinosarcomas and pulmonary blastomas. In the future it is to be expected that these developments will be further refined, e. g. by adding further subtypes for adenocarcinomas and cytologic and/or nuclear criteria for adenocarcinoma and/or squamous cell carcinomas.
authors.affiliation: Institut für Allgemeine und Spezielle Pathologie, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. Gebäude 26, 66421, Homburg/Saar, Deutschland. rainer.bohle@uks.eu.
authors.forename: R M
authors.initials: RM
authors.lastname: Bohle
authors.affiliation: Institut für Allgemeine und Spezielle Pathologie, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. Gebäude 26, 66421, Homburg/Saar, Deutschland. philipp.schnabel@uks.eu.
authors.forename: P A
authors.initials: PA
authors.lastname: Schnabel
mesh_terms: D000230:Adenocarcinoma / Q000145:classification / Q000473:pathology* / Q000628:therapy; D018287:Carcinoma, Large Cell / Q000145:classification / Q000473:pathology / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000145:classification / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000145:classification / Q000473:pathology* / Q000628:therapy; D002296:Carcinosarcoma / Q000145:classification / Q000473:pathology / Q000628:therapy; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D060787:Neoplasm Grading; D011379:Prognosis; D018202:Pulmonary Blastoma / Q000145:classification / Q000473:pathology / Q000628:therapy; D014944:World Health Organization
keywords: Adenocarcinomas; High grade; Rare lung tumors; Squamous cell carcinomas; WHO classification